March 12, 2021
Sosei Group said on March 11 that Taiwan’s Formosa Pharmaceuticals has launched a PIII trial in the US for APP13007, an inflammation and pain drug used after cataract surgery, triggering a milestone payment of US$2.5 million. APP13007 is a nanoparticle...read more